Replies to post #73385 on Biotech Values

[DewDiligence]

IDIX ReadMeFirst

[Updates:
new version of “HCV: Most Likely to Succeed”;
revised table of insider shareholdings;
fair market value of Tyzeka royalty stream.]


What is IDIX’s business all about?
#msg-35432611 IDIX now a ‘pure play’ HCV company
HCV synopsis from IDIX website
#msg-26915744 Addressable markets for antiviral drugs (Datamonitor)


Valuation and finances
#msg-35671327 4Q08 financial results
#msg-35706808 Musings on IDIX’s liquidity
#msg-35740500 Fair market value of Tyzeka royalty stream
#msg-29157548 Standstill agreement with NVS has expired
#msg-35646213 Table of recent biotech buyouts


News flow
#msg-35672427 2009 clinical goals


Officers, directors, and major shareholders
#msg-35471801 Composition of Board of Directors
Capsule résumés of executive officers (click on a name)
#msg-33807169 Largest shareholders
#msg-29157548 Standstill agreement with NVS has expired
#msg-33807081 Latest NVS “true up” purchase
#msg-33625817 NVS’ cost basis
#msg-35737993 Current insider shareholdings
#msg-32238060 Recent insider transactions


HCV program: Economic rationale and competition
#msg-35738787 HCV: Most Likely to Succeed (IMHO)
HCV drugs on market and in development
#msg-29018192 Prevalence and incidence of HCV in the US
#msg-30190435 Devastating risk of undertreating HCV
#msg-34694166 US prevalence of genotypes 1a and 1b
#msg-34772664 Role of interferon in future combination therapy


HCV program: IDX184 nucleotide polymerase inhibitor
#msg-26915921 Why IDX184 is better than NM283
#msg-34771363 Nucleoside vs nucleotide
#msg-34763865 Phase-1/2 monotherapy study
#msg-28715477 Preclinical data


HCV program: IDX375 non-nucleoside polymerase inhibitor
#msg-31043481 Introducing IDX375
#msg-34334563 Blurb on IDX375 from hivandhepatitis.com
#msg-34677952 Comments on the non-nucleoside “class”


HCV program: IDX136/316 protease inhibitors
#msg-31043481 Introducing IDX136 and IDX316
#msg-35628221 Rationale for IDX136/316 and distinction between them


HIV program
#msg-35391933 IDIX inks worldwide partnership with GSK
#msg-35447718 The New Battle Lines in HIV
#msg-35630218 Musings on the GSK deal from pipelinereview.com
#msg-35640675 IDX899 could be combined with GSK’s integrase inhibitor
#msg-35641975 What to look for from GSK in the coming months
#msg-35137606 Market data from GILD’s 4Q08 CC
#msg-35674369 HIV market overview (2007 article from CNNMoney)
#msg-34385301 Also-ran players in HIV market (market-share chart)
HIV drugs on market and in development
#msg-31175781 HIV incidence in US is higher than previously thought
#msg-35109525 Sustiva (which IDX899 might supersede) sells $1.2B/yr
#msg-31419107 Increased HIV screening will expand market
#msg-33124429 New guidelines to recommend earlier treatment
#msg-33898893 Half of untreated US carriers are in 350-500 CD4 range
#msg-29985830 Design of a late-stage HIV trial


Reference links
http://www.idenix.com/hepc/about
http://www.hcvdrugs.com/
http://www.hivandhepatitis.com
http://www.aidsmeds.com/list.shtml